Subtype
B-Lymphoblastic Leukemia/Lymphoma with Recurrent Genetic Abnormalities
CI-CAN-00009459Explore in graph →
Hematologic20 active trials98 evidence items
Loading cancer entity…
Subtype
CI-CAN-00009459Explore in graph →
Clinical trials
46 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (6)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07454226 | ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL | recruiting | N/A | 92 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT06481228 | Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL | recruiting | N/A | 82 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Mar 2, 2026 |
| clinicaltrials |
| NCT05024357 | A Study of TKI Maintenance Therapy Following Allo-HSCT in Newly Diagnosed Ph+ Adult ALL | unknown | N/A | 80 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Oct 1, 2021 | clinicaltrials |
| NCT05026229 | A Study of Dasatinib Plus Reduced Intensive Consolidation Chemotherapy in Ph+ Adult ALL | unknown | N/A | 60 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Oct 1, 2021 | clinicaltrials |
Data updated 23 days agoSource updated May 13, 2026source: clinicaltrials